Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EB-203 in neovascular age-related macular degeneration
NCT06487039Phase 2Recruiting
- Sponsor
- EyebioKorea
- Start
- Aug 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of EB-203 in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by EyebioKorea. Primary endpoint: Change in central retinal thickness at 12 weeks. Started Aug 2024; status: recruiting.
02
Drugs
EB-203
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT06487039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06487039.